AUTHORS
Naveen Pemmaraju, MD, Quan Chen, PhD, MS2, Yangyang Liu, PhD3, Sima Patel, PhD4, Jalaja Potluri, MD5, Annie McNeill6, Kendra L. Sweet, MD, MS7
AFFILIATIONS
1 MD Anderson Cancer Center, Houston, Texas, United States
2 AbbVie Inc., North Chicago, Illinois, United States
3 AbbVie Inc., North Chicago, Illinois, United States
4 AbbVie Inc., North Chicago, Illinois, United States
5 AbbVie Inc., North Chicago, Illinois, United States
6 AbbVie Inc., North Chicago, Illinois, United States
7 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
ABSTRACT
Background: BPDCN is a rare and clinically aggressive hematological malignancy, marked by progressive skin, bone marrow, lymph node, and central nervous system involvement, underscoring a need for timely and early diagnosis. Recognized as a distinct myeloid neoplasm by the World Health Organization (WHO) in 2016 and subsequently reclassified under dendritic cell neoplasms in 2022 (WHO 5th edition), the BPDCN diagnostic journey is often complex and spans several months. Diagnosis generally involves progression from dermatological examination through to hematologic confirmation. Since BPDCN shares clinical and diagnostic features with acute leukemias and aggressive T-cell lymphomas, differential diagnosis is challenging. RW evidence is needed to characterize the BPDCN diagnostic journey.
Methods: This RW, retrospective, US-based study utilized the Flatiron Health electronic health record–derived database to examine the diagnostic journey for patients with BPDCN between January 1, 2011 and June 30, 2025. Eligible patients had BPDCN (International Classification of Diseases [ICD] system; ICD-10 code C86.4x) or evidence of structured order or administration of tagraxofusp; ≥2 documented clinical visits on different days on or after January 1, 2011; and BPDCN diagnosis confirmed by chart abstraction. Clinician visits prior to BPDCN diagnosis were collected from physician notes, including clinician types, diagnosis of skin condition, biopsy details, and prior hematologic malignancies. Descriptive statistical analysis was conducted to examine clinician types treating initial skin presentation prior to and at BPDCN diagnosis, time interval from the first documented clinical manifestation to diagnosis of BPDCN, the most common sites at diagnosis, and types of initial skin presentation or skin manifestation.
Results: A total of 199 patients met inclusion criteria for this analysis; 166 (83%) were male,161 (81%) were non-Hispanic, and 140 (70%) were White; 43 (22%) had prior or concurrent hematologic malignancies (PCHM). Median (IQR) age at diagnosis was 71.0 (60.0–79.0) years.
Overall, 66 (33%) patients had records of ≥1 clinician visit prior to BPDCN diagnosis for the management of initial skin presentations; of these, 20 (30%) were dermatology only, 16 (24%) were general practice only, 14 (21%) were “other” only, and 16 (24%) visited >1 type of clinician. Of 66 patients with prior visits, skin lesions, rash, and infection were present in 33 (50%), 20 (30%), and 13 (20%) patients, respectively. Extramedullary disease was present in 61 (92%) patients, most commonly affecting the skin (n=55 [83%]) and lymph nodes (n=15 [23%]); skin biopsy was the most common tissue source (n=49 [74%]), with bone marrow biopsy only used for 11 (17%) patients to confirm BPDCN diagnosis; the most common PCHMs were myelodysplastic syndrome (n=9 [14%]), chronic myelomonocytic leukemia (n=6 [9%]), and acute myeloid leukemia (n=4 [6%]). Median (IQR) time from first clinician visit pre-diagnosis to BPDCN diagnosis was 69 (18–168) days. Comparing visits on diagnosis (n=35) vs pre-diagnosis (n=117), skin lesions, rash, and infection were present in 21 (60%) vs 42 (36%), 10 (29%) vs 23 (20%), and 1 (3%) vs 21 (18%) patients, respectively.
Among all patients, 186 (93%) had immunophenotyping testing at any time, including all 4 key markers (CD123/CD4/CD56/TCL1), and only 19 (10%) were tested before diagnosis. Of 86 patients with a clinician visit, 20 (23%) were diagnosed at their first visit with 27 (31%) and 12 (14%) diagnosed later than 3 and 12 months after their first visit, respectively.
Conclusion: This RW study highlights major delays in BPDCN diagnosis. Bone marrow biopsy and immunophenotyping testing remain underutilized prior to diagnosis. Dermatologists and general practitioners were the most frequently involved clinicians pre-diagnosis. Nonspecific skin nodules and lesions were the predominant initial skin presentation, underscoring the diagnostic challenge posed by BPDCN's resemblance to common dermatologic conditions. There is an unmet need for increased awareness across the multidisciplinary team, including dermatologists, hematopathologists, and heme-oncologists to facilitate timely and accurate diagnosis and treatment initiation.
DISCLOSURES
Naveen Pemmaraju, MD: HemOnc Times/Oncology Times - Other (including travel support); Physician’s Education Resource - Honoraria; MDEducation - Honoraria; PVEK - Honoraria; Indy Hematology Education - Honoraria; Synapse Medical Communications - Honoraria; Takeda - Research Funding; Johnson & Johnson - Research Funding; US Department of Defense - Research Funding; AbbVie - Research Funding; Institutional funding from US Department of Defense - Research Funding; Meiji - Research Funding; Opna bio LLC - Research Funding; National Institutes of Health/National Cancer Institute (NIH/NCI) - Research Funding; Karyopharm Therapeutics - Research Funding; Sager Strong Foundation - Research Funding; Incyte - Research Funding; Menarini-Stemline Therapeutics - Research Funding; Disc Medicine - Research Funding; Karger Publishers - Patents & Royalties; ASH Committee on Communications - Consultancy (Includes expert testimony); Disc Medicine - Consultancy (Includes expert testimony); Dava Oncology - Consultancy (Includes expert testimony); Karyopharm Therapeutics - Consultancy (Includes expert testimony); Menarini-Stemline Therapeutics - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Patient Power - Consultancy (Includes expert testimony); Harborside Press - Consultancy (Includes expert testimony); Meiji - Consultancy (Includes expert testimony); Eli Lilly & Co - Consultancy (Includes expert testimony); Bristol-Myers Squibb - Consultancy (Includes expert testimony); Aptitude Health - Consultancy (Includes expert testimony); HemOnc Times/Oncology Times - Consultancy (Includes expert testimony); Celgene - Consultancy (Includes expert testimony); Aplastic Anemia and MDS International Federation - Consultancy (Includes expert testimony); Medscape - Consultancy (Includes expert testimony); CTI BioPharma Corporation - Consultancy (Includes expert testimony); MorphoSys - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Menarini Group - Consultancy (Includes expert testimony); Paylex - Consultancy (Includes expert testimony); EUSA Pharma - Consultancy (Includes expert testimony); Silence Therapeutics - Consultancy (Includes expert testimony); Cimeio Therapeutics - Consultancy (Includes expert testimony); Clearview Healthcare Partners - Consultancy (Includes expert testimony); Cogent Biosciences - Consultancy (Includes expert testimony); Blueprint Medicines - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony); OncLive - Consultancy (Includes expert testimony); Intellisphere - Consultancy (Includes expert testimony); Magdalen Medical Publishing - Consultancy (Includes expert testimony); Curio Science - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); BeONe - Consultancy (Includes expert testimony); Dan's House of Hope - Consultancy (Includes expert testimony); Immunogen - Consultancy (Includes expert testimony); Opna bio LLC - Consultancy (Includes expert testimony); Pacylex - Consultancy (Includes expert testimony); Imedex - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony); Astellas Pharma - Consultancy (Includes expert testimony); Cimeio Therapeutics AG - Consultancy (Includes expert testimony); Physician’s Education Resource - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); CareDx - Consultancy (Includes expert testimony); CancerNet - Consultancy (Includes expert testimony); Neopharm - Consultancy (Includes expert testimony); ASCO Cancer.Net Editorial Board - Consultancy (Includes expert testimony); PeerView Institute for Medical Education - Consultancy (Includes expert testimony); Neopharm - Consultancy (Includes expert testimony); Cimeio Therapeutics AG - Speakers Bureau.; Paylex - Speakers Bureau.; Cimeio Therapeutics AG - Membership on a Board/Advisory Committee; Paylex - Membership on a Board/Advisory Committee; Dan’s House of Hope - Membership on a Board/Advisory Committee